The size of the Global RNAi Drug Delivery Market was worth USD 39.4 billion in 2019 and is expected to reach USD 131.2 billion by 2024, growing at a CAGR of 27.2 % during the forecast period 2019 - 2024.
RNAi is a defense mechanism employed by Eukaryotes to degrade exogenous genes such as viruses. It is exclusively called gene silencing. We can initiate this by injecting RNAi-based drugs into the human body which is called RNAi Drug Delivery. RNAi Drug Delivery is an emerging therapeutic method. This method is specific to the point and has fewer side effects. It is possible to cure cancer with this method by controlling gene mutation. From 2006 onwards various clinical trials are being held and people are investing billions in this market to approve and research various types of RNAi-based Drugs.
Some factors like the Increasing prevalence of chronic diseases like cancer and heart diseases and innovative Applications of the drug delivery market are driving this market. In addition, Research carried out in the RNA Therapeutic field has also amplified the growth in the Global RNA Drug Delivery Market.
The rise in account of chronic diseases such as cancer and cardiac malfunctioning are leading to a constant increase in demand for the RNAi drug delivery market across the world. Government authorities in developing countries are taking measures for providing advanced drug delivery options to all sections of people to enhance healthcare services which are fuelling the growth of the Gloval RNAi drug delivery market. Also, medical research organizations are continually putting efforts for developing effective RNA therapeutics, and an increasing number of academic research and activities are also catalysing the growth of the global RNAi drug delivery market. Other factors boosting the growth of the market are increased adoptions of innovative drug delivery technologies, enhancement of drug by improving stability. Also, it reduces the risk of side effects and other complications in patients.
But, High investment and strict regulations are some of the major restraints to this market. Delivery of RNAi Drugs to specific tissues is the key challenge faced by the market.
High costs associated with research are restraining the market and are expected to challenge the growth of the global RNAi drug delivery market. Other factors that are challenging the growth of the market are inappropriate regulations, high risk of failure, shortage of skilled professionals in drug control laboratories, and lack of proper distribution networks of RNAi drug delivery due to the inadequate infrastructure of healthcare in developing countries. Accurate delivery of RNA molecules is one of the critical challenges to the companies that are involved in the Global RNAi drug delivery market.
Increased focus of research and development activities from the private and public organizations on nanotechnology to meet the continually rising demand of the RNAi drug delivery method, is expected to be creating more growth opportunities for the market over the forecast period. Increasing economies of the countries such as UK, Canada, and highly populated countries such as China and India, where the healthcare is booming rapidly is creating a wide range of opportunities for the stakeholders and others involved in the Global RNAi drug delivery market.
Key Developments in this Market in the Recent Past:
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 – 2024 |
|
Segments Analysed |
By Drug Delivery, Therapeutic Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
|
Companies Analysed |
Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Tekmira Pharmaceuticals Corp, Isis Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Traversa Therapeutics Inc, Tacere Therapeutics Inc, Sirnaomics Inc, PhaseRx Inc |
This research report on the Global RNAi Drug Delivery Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
RNAi Drug Delivery Market - By Drug Delivery:
On the basis of drug delivery, Nanoparticle Drug Delivery is the largest sub-segment in this market because of its use in the selected delivery of drugs. However, aptamer drug delivery technology is the fastest-growing segment.
RNAi Drug Delivery Market - By Therapeutic Application:
Regional Analysis:
North America has the largest share in the market followed by Europe because of its high investments. However, the Asia-Pacific market is expected to increase at the highest CAGR in the following five years because of increasing investments by the major players in this region
List of key market players dominating the Global RNAi Drug Delivery Market profiled in this report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug delivery
5.1.1 Introduction
5.1.2 nanoparticle drug delivery technology
5.1.3 pulmonary drug delivery technology
5.1.4 nucleic acid drug delivery technology
5.1.5 aptamer drug delivery technology
5.1.6 Y-o-Y Growth Analysis, By Drug Delivery
5.1.7 Market Attractiveness Analysis, By Drug delivery
5.1.8 Market Share Analysis, By drug Delivery
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 infectious diseases
5.2.3 cardiology
5.2.4 oncology
5.2.5 neurology
5.2.6 ophthalmology
5.2.7 metabolic disorders
5.2.8 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.9 Market Attractiveness Analysis, By Therapeutic Application
5.2.10 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Delivery
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Delivery
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Delivery
6.1.5.3 By Therapeutic Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alnylam Pharmaceuticals Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co. Inc
8.3 Access Pharmaceuticals Inc.
8.4 Dicerna Pharmaceuticals Inc.
8.5 Tekmira Pharmaceuticals Corp.
8.6 Isis Pharmaceuticals Inc
8.7 Calondo Pharmaceuticals Inc.
8.8 Marina Biotech Inc.
8.9 RXi Pharmaceuticals Corp
8.10 Quark Pharmaceuticals Inc
8.11 Silence Therapeutics plc
8.12 Traversa Therapeutics Inc.
8.13 Tacere Therapeutics Inc
8.14 Sirnaomics Inc.
8.15 PhaseRx Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
